Elevian CEO to Chair and Present at Longevity Therapeutics Summit
ALLSTON, MA (January 7, 2020) – The 2nd Annual Longevity Therapeutics Summit will be held on January 28-30 in San Francisco, CA. The Summit highlights the latest developments in aging research and therapeutics that target age-related conditions. Elevian CEO, Mark Allen, will chair and present at the pre-conference workshop on January 28.
According to the conference organizers, we are currently at the turning point in longevity biotechnology. In the last few years, there have been major scientific breakthroughs in our understanding of the underlying biology of age-related diseases. This has opened exciting doors for the development of innovative therapies and drugs that can target, reverse or delay the onset of age-related conditions, and consequent health span improvement. Longevity biotechs such as Elevian are embracing exciting opportunities to accelerate candidates from preclinical to clinical stages. Dedicated to enhancing scientific and commercial development of therapeutic options for age-related diseases, this Summit will unite leading biotech drug developers, academics, investors and pharma companies endeavoring to develop innovative anti-aging drugs and overcome key preclinical, translational, clinical and regulatory challenges going forward.
Dr. Allen will chair the pre-conference workshop on January 28. The first session “Deep Dive into the Hallmarks of Aging” will explore the cellular and molecular changes or ‘hallmarks of aging’. In this session, the speakers will delve deeper into the hallmarks through talks, in-depth Q&A and group discussions. Speakers include Aubrey De Gray, PhD, Chief Science Officer, SENS Research Foundation; Irina Conboy, PhD, Professor of Bioengineering, UC Berkeley; and Bill Andrews, CEO, Sierra Sciences.
The second session “Progressing your Pipeline into the Clinic” will share best practices for bringing new drugs into and through clinical trials. Speakers include Mark Allen, MD, CEO, Elevian; Elizabeth Jeffords, Chief Commercial & Strategy Officer, Alkahest; and Robert Molinari, CEO, Retrotope. Dr. Allen will share Elevian’s framework for Indication selection when targeting aging, including a careful analysis of scientific data, regulatory pathway and commercial opportunity.
Come join Dr. Allen and leading authorities in the emerging longevity biotech community at the 2nd Annual Longevity Therapeutics Summit on January 28-30, 2020.
Elevian is an emerging biotech company developing medicines that restore youthful regenerative capacity, with the potential to treat and prevent age-related diseases. Elevian’s scientific founders, working at the Harvard Department of Stem Cell and Regenerative Biology, discovered that replenishing the circulating factor GDF11 can regenerate the heart, brain, muscle and other tissues. Elevian has acquired exclusive, worldwide rights to Harvard’s patent portfolio concerning circulating factors that regulate aging. The company is developing new medicines that target the GDF11 pathway. Elevian’s lead drug candidate (recombinant human GDF11) has demonstrated efficacy in preclinical models of stroke, heart failure, Alzheimer’s disease, Type 2 diabetes, and age-related muscle dysfunction. The company has also established additional programs focused on the discovery and development of novel proteins, antibodies and small molecule drugs that target the GDF11 pathway.